De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression.
Tangudu NK, Buj R, Wang H, Wang J, Cole AR, Uboveja A, Fang R, Amalric A, Yang B, Chatoff A, Crispim CV, Sajjakulnukit P, Lyons MA, Cooper K, Hempel N, Lyssiotis CA, Chandran UR, Snyder NW, Aird KM.
Tangudu NK, et al. Among authors: cole ar.
Cancer Res Commun. 2024 Apr 16. doi: 10.1158/2767-9764.CRC-23-0450. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 38626341
Free article.